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Central to Parkinson’s Disease?
90% (Hughes et al., 2001). It is important to make a
distinction between patients with PD and those with
other forms of parkinsonism, since the cause of the
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preventive therapeutics. Moreover, the fate of dopamin-
ergic neurons has been the focus of most of the research
related to PD, but many other populations of neurons,Parkinson’s disease (PD) is the most common neuro-
degenerative movement disorder. The major motor particularly in late stages of the disease, are also af-
fected to varying degrees in the brainstem and basaldisabilities of PD are associated with the extensive
loss of dopaminergic neurons in the substantia nigra forebrain of PD patients (Forno, 1996), and this may not
be the case in other forms of parkinsonisms.pars compacta. The physiological changes and bio-
chemical pathways involved in the selective demise The identification of a specific point mutation
(Ala53Thr) in the -synuclein (-syn) gene in kindredof these neurons are still unclear. Recent studies have
demonstrated that alterations or reductions in ubiqui- with PD, followed by a multitude of histological and
biochemical studies, has demonstrated that-syn mole-tin-mediated proteasome function can be causal of at
least some forms of parkinsonism, and multiple lines cules are the primary building blocks of the 10 nm
fibrils that form LBs (see Figure 1) (Goedert, 2001). Al-of evidence suggest that this mechanism of protein
degradation may play an important role in the etiology though -syn is normally a soluble monomeric presyn-
aptic protein, it can undergo a dramatic biophysical con-of PD.
formational change acquiring a predominantly  pleated
sheet structure, which facilitates polymerization into fi-
brils (Goedert, 2001). Moreover, the accumulation ofParkinson’s Disease and Related Disorders
Parkinson’s disease (PD) is the most common neurode- other types of intracytoplasmic filamentous -syn inclu-
sions (Figure 1) within neurons (e.g., cortical LBs andgenerative movement disorder, with prevalence that in-
creases with age and afflicts 1% of the population at Lewy neurites) or oligodendrocytes (glial cytoplasmic
inclusions) is characteristic of a spectrum of neurode-the age of 65 years. PD patients exhibit classical clinical
symptoms including bradykinesia (slowed movement), generative diseases termed -synucleinopathies (Goe-
dert, 2001).resting tremor, rigidity, and postural instability. These
clinical features, in combination with responsiveness to The autosomal inheritance of the Ala53Thr -syn mu-
tation, as well as the presence of -syn pathologicallevodopa and some exclusion factors, are important
criteria used in the clinical diagnosis of PD (Gelb et al., inclusions (i.e., LBs and Lewy neurites) in PD, provide
unequivocal evidence that the aberrant fibrillization of1999). However, these clinical features alone can only
be used to establish a probable or possible diagnosis -syn to form inclusions is a key factor in the etiology
of PD. However, several other genes have been identi-of PD, and postmortem examination is needed for the
definite diagnosis of PD (Gelb et al., 1999; Forno, 1996). fied that are causal of parkinsonism. Significantly, a
number of studies (discussed below) suggest that theseA significant loss (70%–90%) of dopaminergic neurons
in the substantia nigra pars compacta (SNc) and the genes, which are involved in ubiquitination and protea-
some-mediated protein degradation, may also play apresence of intracytoplasmic inclusions known as Lewy
bodies (LBs) in some of the remaining dopaminergic role in the demise of dopaminergic neurons in classical
PD. However, in order to elaborate on the relevance ofneurons are signature hallmarks of PD (Forno, 1996). LBs
are round eosinophilic inclusions (Figure 1) comprised of these results, we will first delineate the different pro-
posed mechanisms of -syn toxicity and describe thea halo of radiating fibrils and a less-defined core (Forno,
1996). basic steps that accomplish ubiquitin-mediated protea-
somal degradation.The predominant cause of parkinsonian motor disabil-
ities is the profound reduction in striatal dopamine con-
tent due to the demise of dopaminergic neurons (Forno, Mechanism(s) of -Syn Toxicity
1996). Other neurodegenerative diseases, such as multi- One of the major complexities in determining the signifi-
ple system atrophy (MSA) and progressive supranuclear cance of the results from different research groups
palsy (PSP), can present with parkinsonism and, in some stems from the controversy over the mechanism by
cases, may be difficult to distinguish from PD clinically which -syn causes the demise of cells. At least three
(Hughes et al., 2001). Furthermore, some patients with different mechanisms of toxicity (summarized below)
mutations in the tau gene associated with frontotempo- have been suggested, and it is important to emphasize
ral dementia with parkinsonism linked to chromosome that although these different alternative mechanisms of
17 (FTDP-17) present with prominent parkinsonism. -syn toxicity are not unanimously accepted by all inves-
Even in specialized movement disorder centers, the ac- tigators in the field, they are not necessarily mutually
curate clinical diagnosis of PD can vary between 80%– exclusive either.
Evidence from in vitro studies, transgenic Drosophila,
and mouse models and the analysis of autopsy speci-*Correspondence: vmylee@mail.med.upenn.edu
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fore, it is likely that -syn inclusions can impair cellular
function by obstructing normal cellular trafficking and
disrupting cell morphology, as well as trapping other
cellular components, which can eventually lead to cell
death.
Although the preponderance of evidence supports the
idea that -syn toxicity is linked to the formation of
pathological inclusions, Lansbury and colleagues are
strong advocates that protofibrils may be toxic (Gold-
berg and Lansbury, 2000). This notion is analogous to
the hypothesis that protofibrils of the A peptide in-
volved in Alzheimer’s disease or polyglutamine expan-
sion proteins associated with spinocerebellar ataxias
may be toxic (Goldberg and Lansbury, 2000). The evi-
dence for the toxic nature of -syn protofibrils relies
predominantly on in vitro data (Goldberg and Lansbury,
2000). For example, mutant Ala30Pro -syn causal of
autosomal dominant parkinsonism (autopsies have not
been reported to confirm PD) was reported to have a
tendency to accumulate as protofibrils instead of mature
fibrils (Goldberg and Lansbury, 2000). However, the
toxic nature of A30P -syn protofibrils has not been
validated in vivo since the expression of A30P human
-syn in transgenic mice in the absence of inclusions
does not lead to neurodegeneration (Dawson et al.,
2002). Thus, if Ala30Pro -syn protofibrils indeed cause
degeneration, it should be possible to observe degener-
ation without inclusions, and that degeneration could
be correlated with the formation of protofibrils. However,
such findings have not been observed (Dawson et al.,
2002). Furthermore, Lee et al. (2002) demonstrated a
correlation of neurodegeneration with inclusions forma-
Figure 1. -Syn Pathological Inclusions Immunoreactive for Ubi- tion in transgenic mice overexpressing Ala53Thr human
quitin -syn driven by the mouse prion protein promoter, while
Appearance of classical nigral LBs stained with hematoxylin and equivalent expression of Ala30Pro human -syn without
eosin (HE) or immunostained for -syn in dopaminergic neurons of inclusions did not lead to any form of degeneration.
the SNc in a patient with PD (top). Cortical (c) LBs and glial cyto-
Moreover, if -syn protofibrils are indeed toxic, thisplasmic inclusions (GCIs) immunostained for -syn in patients with
could be demonstrated by microinjecting purified -syndementia with LBs and MSA, respectively (middle). Nigral LB and
protofibrils in cells or by identifying artificial mutantsGCIs immunostained for ubiquitin (bottom).
of -syn that predominantly form protofibrils and then
expressing these proteins in cells. Nevertheless, it has
mens indicate that the aberrant polymerization of -syn been proposed that the formation of -syn protofibrils
into filaments, which eventually form large intracytoplas- with an annular appearance may integrate into mem-
mic inclusions, can lead to the dysfunction and demise brane, resulting in the formation of pores that could
of neurons or oligodendrocytes (Goedert, 2001; Dawson cause uncontrolled membrane permeability (Goldberg
et al., 2002). Some of this evidence includes the in- and Lansbury, 2000), but the presence of these annular
creased propensity of a mutant of -syn (Ala53Thr) to structures appear to be very rare even in vitro.
fibrillize in vitro, as well as the widespread and abundant The third proposed mode of -syn toxicity involves
distribution of -syn pathology in individuals carrying the simple overabundance of -syn. In cultured cells,
the Ala53Thr -syn mutation associated with neurode- -syn expression can result in both neuroprotection and
generation (Goedert, 2001; Duda et al., 2002). Similarly, degeneration (see Xu et al., 2002, and references within),
expression of Ala53Thr human -syn in mice can result but it seems that increased -syn levels can be espe-
in the formation of abundant -syn inclusions that are cially toxic to dopaminergic neurons. The production of
accompanied by severe neuronal dysfunction and axo- dopamine and the formation of -syn complexes with
nal degeneration that leads to death (Dawson et al., other proteins appear to be important for the observed
2002). Furthermore, in humans, LB density and the toxicity of -syn (Xu et al., 2002). In fact, -syn can
more-abundant Lewy neurites correlate with disease se- interact with many proteins and modulate the activity
verity in another neurodegenerative disease known as of several enzymes, including some involved in signal
dementia with LBs (Goedert, 2001; Mattila et al., 1998). transduction pathways. In support of the notion that
Also indicative of the toxic role of -syn aggregates are increased expression of -syn may play a role in the
glial cytoplasmic inclusions (GCIs) (see Figure 1) in MSA. demise of dopaminergic neurons, higher levels of -syn
These abundant -syn inclusions are almost exclusively were observed in the SN of a set of PD patients (Xu et
associated with MSA, and they can fill almost the entire al., 2002). On the other hand, elevated levels of -syn
in SN has not been reported in other studies, and thecytoplasm of oligodendrocytes (Goedert, 2001). There-
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chains, which can act as signals for proteasome-medi-
ated degradation (Hochstrasser, 1996). The 26S protea-
some is composed of two major components, the 19S
cap and the 20S core protein complexes. The 20S core
complex is basically a cylinder with a narrow opening
at both ends, and the proteolytic activities reside within
the hollow transversal cavity. The 20S complex by itself
is active, but only small peptides and unfolded elon-
gated proteins can enter the openings (see Figure 2B).
The 26S proteasome machinery consists of two 19S
complexes that sit at both ends of the 20S barrel. The
19Scomplex is involved in the recognition of polyubiqui-
tinated substrates, assists in the unfolding of the target
protein for entry into the opening of the cylinder, and
cleaves off the polyubiquitinated chain from the sub-
strate (see Figure 2C).
Recognition of the substrates by the proteasome is
enhanced by longer polyubiquitin chains, and tetraubi-
quitin appears to be the minimum signal for efficient
Figure 2. Schematic Representations of the Basic Ubiquitation targeting to the proteasome (Thrower et al., 2000). On
Pathways and Proteasome Complex
the other hand, monoubiquitination can serve other
(A) The covalent addition of multiple ubiquitin (Ub) moieties to pro-
functions, such as signaling the internalization of trans-teins requires three major activities. The E1 enzyme activates ubiqui-
membrane protein by the endocytic pathways (Hoch-tin by forming a thiol ester linkage in a reaction that requires the
strasser, 1996). The selectivity of ubiquitination is largelyhydrolysis of ATP. This activated ubiquitin molecule is then trans-
ferred to an E2 carrier protein. An E3 ligase protein complex is mediated by the recognition of substrates by E3, and
responsible to recruit the substrate, and ubiquitin is transferred to posttranslation modifications, such as phosphorylation
the target protein. of the substrate, can regulate this interaction. Moreover,
(B) The 20S proteasome apparatus can be viewed as a basic cylin-
a group of enzymes known as deubiquitinating enzymesder, and natively unfolded proteins can enter through the narrow
or ubiquitin-specific peptidases can also be involvedopening at either end of the cylinder to be degraded.
in modulating the extent of ubiquitination by removing(C) The complete 26S machinery is composed of the 20S cylinder
and a 19S cap protein complex that sits at both ends of the cylinder ubiquitin moieties. These enzymes also serve to gener-
(note that only one 19S complex is depicted in this cartoon). The ate mature monoubiquitin from preubiquitin forms, to
19S complex recognizes polyubiquitinated proteins and assists in break down polyubiquitin chains liberated by the protea-
their unfolding to enter the proteolytic cylinder. The polyubiquitin
some, and to regenerate free ubiquitin that can readilychain is released by the 19S subunit, and it is further degraded to
form adducts with abundant intracellular nucleophilesfree ubiquitin by enzyme-like ubiquitin carboxy-terminal hydrolase
such as amines and glutathione (Hochstrasser, 1996).(UCH).
Defects in the E3 Ligase Parkin Are a Cause
loss of dopaminergic neurons in the SN has not been of Juvenile and Early-Onset Parkinsonism
observed in transgenic mice that overexpress high lev- Mutations in the parkin gene are the most common sin-
els of -syn (Dawson et al., 2002). gle factor that is responsible for juvenile (21 years) and
early (45 years)-onset parkinsonism, and mutations in
this gene are responsible for 50% of individuals withRegulation of Ubiquitination
and Substrate Selectivity this disorder if they have a family history. The parkin
gene was initially identified as the genetic defect respon-Ubiquitin is an abundant 76 amino acid polypeptide that
can be covalently conjugated to specific proteins by the sible for a disease entity known as autosomal recessive
juvenile parkinsonism (AR-JP) in a Japanese populationformation of an isopeptide bond between its carboxyl
terminus and the amino group of a lysine residue of the (Kitada et al., 1998). In most cases, parkinsonism linked
to parkin is associated with the loss of function of bothtarget proteins. This process requires several enzymes
that are needed to ensure specificity and to activate the alleles. However, in a small subset of patients, methodi-
cal analysis including sequencing of the entire codingubiquitin moiety (see Figure 2A). The first step involves
the ubiquitin-activating enzyme (E1), which forms a thiol region, the promoter region, and intron/exon bound-
aries, and assessment of exonic deletion and duplica-ester linkage between a cysteine residue and the car-
boxy-terminal glycine in ubiquitin in an ATP-dependent tion revealed a genetic alteration on only one allele (West
et al., 2002). Therefore, it is possible that parkin haplo-manner (Hochstrasser, 1996). This activated ubiquitin
moiety is then transferred to one of several possible insufficiency can lead to disease, but it is difficult to
completely exclude the possibility that some other mu-carrier proteins (E2s) via the formation of another thiol
ester linkage. Finally, ubiquitin is specifically transferred tation, perhaps within the introns, is present on the sec-
ond allele. So far, parkin mutations in the parkin geneto the substrate with the assistance of an E3 ligase or
ligase complex (Hochstrasser, 1996). include: (1) point mutations, either nonsense or mis-
sense, (2) deletions of one or several exons that canSeveral internal lysine residues (with Lys 48 being the
predominant residue used) within ubiquitin can further result in premature termination of translation or in-frame
deletions, which are predicted to produce shorter pro-be used as substrates to create polyubiquitinated
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teins missing middle segments, (3) duplication or tripli-
cation of exons that result in premature termination of
translation, (4) insertions and deletions of one, two, or
five base pairs, resulting in frameshift mutations, and
(5) mutations at the exon-intron boundaries that affect
the splice donor site (West et al., 2002; Giasson and
Lee, 2001).
Patients with AR-JP associated with loss of parkin
function display the typical clinical features of parkin-
sonism, including marked responsiveness to L-dopa
therapy. However, some of these patients present with
foot dystonia, which is atypical of PD. The onset of
disease is quite variable, ranging from 6–68 years of age,
but typically, it is before 40 years. Neuropathological
examination revealed extensive neuronal loss and glio-
sis restricted to the SNc and the locus ceruleus. How-
ever, in most cases, LBs and Lewy neurites are not
observed, but one exception has been reported (see
Giasson and Lee, 2001, for details).
The obvious importance of parkin in protecting
against the degeneration of dopaminergic neurons of
the SNc has led to many investigations on establishing
the function of this protein and to efforts linking its func-
tion to -syn pathobiology. Parkin is a 465 amino acid
residue protein encoded by a large gene (500 kbp)
on chromosome 6q25.2-q27 (Kitada et al., 1998). It is
characterized by several domains including an ubiquitin-
like region at it extreme amino terminus and two RING
(really interesting new gene) finger motifs separated by
an in-between RING finger (IBR) domain near the car-
boxyl terminus (see Figure 3A). Parkin has been shown
to be able to serve as an E3 ligase through it interaction
with the E2 ubiquitin-carrier proteins Ubc H7 (Shimura
Figure 3. Diagrams of Some Important Elements Associated withet al., 2000; Staropoli et al., 2003) or Ubc H8 (Zhang et
Ubiquitination and Parkinsonismal., 2000), although these studies are at odds with each
(A) Schematic representation of the parkin protein. Parkin consistsother concerning which E2 protein can drive parkin ac-
of several domains: an amino-terminal ubiquitin-like domain (Ub-tivity. Several putative substrates for parkin-mediated
like) and two carboxyl terminal RING finger domains separated by
ubiquitination have been identified including the synap- an in-between RING finger (IBR).
tic vesicle-associated protein CDCrel-1, synphilin-1, a (B) Role of CHIP is facilitating parkin-mediated ubiquination and
homolog of endothelin receptor type B termed Pael-R proteasomal degradation of misfolded Pael-R. Pael-R is shown as
a transmembrane endoplasmic reticulum (ER) protein, and its accu-(Parkin-associated endothelin receptor-like receptor),
mulation in a misfolded conformation is toxic. Hsp70 (or Hsc70) canand an unusual O-glycosylated isoform of -syn (re-
assist in the normal folding of Pael-R. Hsp70 also binds to parkin,viewed in Giasson and Lee, 2001). As an E3 ligase, it
preventing interaction between parkin and Pael-R. Interaction be-has been suggested that parkin could assist in the re-
tween CHIP and Hsp70 promotes the release of parkin from Hsp70.
moval of misfolded proteins in the endoplasmic reticu- Free parkin recognizes misfolded Pael-R, inducing its polyuniquiti-
lum associated with cellular stress. For example, parkin nation and degradation by the proteasome. Additionally, direct bind-
can mediate the proteasome degradation of misfolded ing of CHIP to parkin can further promote parkin E3 activity.
(C) Ubiquityl ligase activity of UCH-L1. The ubiquitin moiety on mo-Pael-R, which can be toxic to cells (Imai et al., 2001).
noubiquitinated -syn (other substrates could also be used) is re-Pael-R is a putative G-protein-coupled transmembrane
moved by the formation of a ubiquitin-UCH-L1 intermediate. Theprotein that, when overexpressed in cultured cells, tends
ubiquitin moiety can be released from UCH-L1 by the classical hy-to become misfolded and form aggregates that can lead
drolysis activity of this enzyme. Alternatively, ubiquitin moieties can
to cell death. Parkin facilitates the ubiquitination and be transferred to ubiquinated -syn molecules, resulting in the ex-
degradation of insoluble Pael-R, thereby suppressing tension of the ubiquitin chain on -syn.
Pael-R-induced cell death. Conversely, insoluble Pael-R (D) Interaction of aggregated -syn with a subunit of the 19S cap
can inhibit the activity of the proteasome.accumulates in the brain of AJ-RP patients with defec-
(E) Polyubiquitinated -syn inclusion may be recognized by the 26Stive parkin (Imai et al., 2001).
proteasome. Because these aggregates are stable and they cannotParkin, like some other E3 ligases, functions within
be unfolded, this interaction can effectively disable the proteasome.protein complexes that modulate its activity and speci-
ficity. CHIP (carboxy-terminal of Hsc70-interacting pro-
tion from parkin and Pael-R, facilitating parkin-mediatedtein) has recently been identified as a modulator of par-
ubiquitination of misfolded Pael-R. Additionally, directkin E3 ligase activity (Imai et al., 2002). It appears that
binding of CHIP to parkin can further augment parkinthe heat shock proteins Hsp70 and Hsc70 can bind to
E3 ligase activity. Collectively, these effects of CHIPboth parkin and Pael-R (see Figure 3B). The interaction
of CHIP with Hsp70 and Hsc70 promotes their dissocia- increase the proteasome-mediated degradation of mis-
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folded Pael-R, attenuating cell death. Interestingly, in- tions in amino acids sequences, it is possible that these
creasing the levels of Hsp70/Hsc70 also reduce Pael-R two parkin molecules form E3 ligase complexes with
toxicity, suggesting that any mechanism that prevents different substrate specificities. Moreover, it is possible
the accumulation of misfolded Pael-R is beneficial. that different parkin binding partners are expressed in
Parkin can also function as an E3 ligase within a novel both organisms, and the redundancies in parkin-like E3
SCF (Skp1, Cullin, and an F box protein)-like complex, ligase activity may not be the same. Another important
which, however, does not include Skp1 (Staropoli et al., difference between both species may be the expression
2003). Within this complex, the ubiquitin ligase compo- of parkin substrates.
nent hSel-10 (an F box/WD protein) appears to interact One of the parkin substrates that could certainly ac-
with the RING domain of parkin, and hSel-10 also re- count for the difference in dopaminergic cell loss in
cruits the protein Cul1. hSel-10 can recognize cyclin E humans and Drosophila is Pael-R, since this protein
as a substrate, and this parkin-SCF-like complex targets does not have a homolog in Drosophila. Transgenic flies
cyclin E for ubiquitination. Consistent with a role for with pan-neuronal expression of human Pael-R demon-
parkin in the degradation of cyclin E, the level of this strate an age-dependent selective degeneration of do-
protein is increased in the SN of a patient with AR-JP paminergic neurons, and bigenic expression of human
associated with a lack of parkin (Staropoli et al., 2003). parkin rescues the degeneration of dopaminergic neu-
A similar increase in cyclin E was observed in patients rons (Yang et al., 2003). Furthermore, the depletion of
with idiopathic PD, suggesting that perhaps parkin func- endogenous Drosophila parkin using RNA interference
tion can be impaired in PD, although this prospect will (RNAi) technique exacerbated the demise of cultured
have to be confirmed by more direct methods. Neverthe- dopaminergic neurons associated with an accumulation
less, in cultured primary cortical neurons, knockdown of Pael-R.
of parkin with short interfering RNAs (siRNAs) results
in increased cyclin E, while increased levels of parkin Potential Role of Parkin in Modulating
attenuates the accumulation of cyclin E following kai- -Syn Toxicity
nate exposure, consistent with the notion that parkin Several clues suggest that parkin can be directly in-
mediates the degradation of cyclin E (Staropoli et al., volved in the removal of certain forms of -syn and
2003). Increased cyclin E activity in postmitotic neurons thereby attenuates -syn toxicity and inclusion forma-
has previously been implicated in apoptotic cell death, tion. Although soluble -syn is not used as a substrate
and the modulation of cyclin E levels in kainate-treated for parkin, a very unusual form of -syn, termed Sp22,
neurons either by overexpressing parkin or suppressing was identified as a parkin substrate (Shimura et al.,
parkin levels coincides with lower or higher toxicity, re- 2001).Sp22 was reported as an O-glycosylated isoform
spectively (Staropoli et al., 2003). Although these results that contains complex monosaccharides chains, but no
suggest that cyclin E may be involved in kainate-induced further information on this form of -syn has been re-
cell death, they demonstrated that parkin levels can ported following the initial study and, therefore, its role
directly influence neuronal sensitivity to kainate. in disease remains unknown. Synphilin-1, another sub-
Due to the increasing complexity of the possible par-
strate for parkin, can promote the formation of -syn
kin interacting/modulator proteins and the increasing
inclusions in cultured cells (Chung et al., 2001). However,
number of putative substrates, it becomes important to
the role of synphilin-1 in the formation of -syn inclu-
clarify and verify the relevant substrate in in vivo studies.
sions in brain is still unclear since it is present in onlyWhile no knockout mice have been reported so far,
a subset of -syn pathological lesions (Wakabayashi etGreene et al. (2003) recently described parkin null Dro-
al., 2002).sophila. These flies exhibit reduced longevity, abnormal
The expression of -syn in dopaminergic neurons ofwing posture, defects in flight and climbing ability, as
Drosophila can result in the death of 50% of thesewell as male sterility due to impaired development of
neurons in the dorsomedial cluster, and this neuronalspermatozoa. The motor dysfunction in these flies was
loss can be attenuated by the expression of parkin (Yangattributed to the selective apoptotic degeneration of
et al., 2003). This rescue occurs with a concomitantthe indirect flight muscles. Overall loss of dopaminergic
reduction in the amount of aggregated “grain-like”-synneurons was not observed, although some of these neu-
structures without affecting the expression levels ofrons exhibit diminished tyrosine-hydroxylase staining
-syn. These results suggest that parkin may specificallyand atrophy.
recognize and target aggregated or fibrillar forms ofThese findings in Drosophila yield more questions
-syn for degradation.than answers concerning the role of parkin in preventing
The expression of mutant forms (Ala30Pro orthe selective vulnerability of dopaminergic neurons in
Ala53Thr) of -syn associated with autosomal dominanthumans. Male sterility and muscle degeneration has not
disease, but not wild-type -syn, can result in a reduc-been reported in AR-JP patients. However, it is possible
tion in proteasome activity that can render cultured neu-that other types of cells besides dopaminergic neurons
roblastoma cells more sensitive to further proteasomeare affected in AR-JP patients, but such findings have
inhibition (see Petrucelli et al., 2002, and referencesnot been observed due to the focus on the parkinsonian
within). Snyder et al. (2003) demonstrated that aggre-features. Nevertheless, differences in parkin itself may
gated -syn can directly inhibit the 26S proteasome byaccount for the disparate effects in both species. The
binding to the S6 protein of the 19S cap (Snyder et al.,Drosophila ortholog of human parkin has significant se-
2003). It is possible that Ala53Thr and Ala30Pro -syn,quence differences with 64% of the residues conserved
which are more prone to assemble into fibrils or protofi-in the RING-IBR-RING region and only 36% conserved
in the remainder of the protein. Because of these varia- brils, respectively, form small aggregates in cells and
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that these aggregates are responsible for the reduction gase activity. The ubiquityl ligase-like activity of UCH-
L1 is probably not specific for -syn, and the samein proteasomal activity. Interestingly, cultured tyrosine
hydroxylase-positive mesencephalic neurons are espe- effect may occur on other substrates. This latter activity
depends on the formation of UCH-L1 dimers or highercially susceptible to proteasome inhibition, and the ex-
pression of Ala53Thr -syn, but not wild-type -syn, can ordered complexes. However, it is unclear whether or
not the UCH-L1 ubiquityl ligase activity occurs in vivolead to the demise of these cells (Petrucelli et al., 2002).
Overexpression of parkin can attenuate both of these under physiology conductions. In contrast to the in vitro
data, increased levels of UCH-L1 expression in culturedtoxicities, suggesting that Ala53Thr -syn may render
dopaminergic cells more fragile by affecting ubiquitin- cells correlate with reduced levels of polyubiquitination
(Imai et al., 2000). For example, FLAG-tagged -syn canmediated protein degradation or parkin may participate
in removing toxic species of Ala53Thr -syn (Petrucelli be polyubiquitinated, and expression of UCH-L1 sup-
presses the levels of polyubiquitinated FLAG-taggedet al., 2002). Furthermore, since parkin promotes the
degradation of specific proteins but does not increase -syn (Imai et al., 2000).
overall proteasome activity, it may enhance the resil-
ience to proteasome inhibition by selectively mediating Ubiquitination of -Syn and Proteasome
the degradation of specific toxic proteins at the expense Function in PD
of others that may be less deleterious. It is well established that LBs and other types of -syn
inclusions contain ubiquitin (see Figure 1), but only re-
cently was it demonstrated that -syn itself within theUCH-L1, a Gene Product Linked to Parkinsonism,
Can Act As a Ubiquityl Ligase inclusions is polyubiquitinated (Hasegawa et al., 2002).
However, the timeline of ubiquitination relative to inclu-A nucleotide substitution resulting in the Ile93Met amino
acid change in the enzyme ubiquitin carboxy-terminal sion formation, which enzyme(s) is responsible for -syn
ubiquitination in inclusions, and the role, if any, thishydrolase L1 (UCH-L1) was identified in two siblings
with parkinsonism (Leroy et al., 1998). Although this find- modification has in the pathophysiology of PD, are only
beginning to be elucidated.ing also appeared to provide further evidence for the
involvement of aberrant ubiquitination pathways in PD, In cultured cells, the ubiquitination of native -syn
has not been observed, although epitope-tagged -synthere are several issues that limit the interpretation of
these findings. It is unclear if these individuals have (e.g., FLAG-tag) can become a target for ubiquitination
(Imai et al., 2000). In vitro, -syn can readily be ubiquiti-PD, since no autopsy has been performed. Furthermore,
there are several factors that put in question whether nated using reticulocyte extracts, but the active compo-
nents responsible for this ubiquitination are unknownthe Ile93Met substitution is a mutation causal of disease.
For example, the mode of transmission of this substitu- (Liu et al., 2002). The issue of whether -syn is degraded
by the proteasome is controversial, since both positivetion seems to be autosomal dominant since only one
UCH-L1 allele is altered. However, the parents of the and negative data have been reported (see Paxinou et
al., 2001, and references within). The reasons for theaffected sibling were unaffected, which indicates that
this substitution could be a rare polymorphism that seg- discrepancies in these results are unclear, but the long
half-life of -syn (48 hr) and the use of nonspecificregates with disease or that it is a mutation with incom-
plete penetrance (Liu et al., 2002). UCH-L1 is a thiol proteases inhibitors, such as MG132, may be contribut-
ing factors. Native unfolded -syn can be degraded byprotease that has been characterized for its ability to
hydrolyze C-terminal bonds between ubiquitin and small the 20S proteasome in vitro (Tofaris et al., 2001) and,
perhaps, when -syn is highly overexpressed in cells,adducts, and the Ile93Met substitution results in only a
partial loss (50%) of catalytic activity (Leroy et al., 1998). it can be partially degraded by the 20S proteasome. It is
also possible that different cell types may have differentTherefore, it is unclear how the simple reduction of the
activity of one of the two copies of the UCH-L1 gene levels of 20S proteasome. Nevertheless, there is no evi-
dence to indicate that native -syn is a target for degra-products could have a dominant effect, especially since
mice completely deficient in UCH-L1 (gracile axonal dys- dation by the 26S proteasome.
The finding that not all -syn inclusions contain ubi-trophy [GAD] mice) display a loss of sensory and motor
neurons, but do not develop a parkinsonian phenotype quitin (Goedert, 2001) indicates that ubiquitination of
-syn is not a prerequisite for inclusion formation. Ubi-(Saigoh et al., 1999). Nevertheless, the identification of
a polymorphism in UCH-L1 (Ser18Tyr) associated with quitination may occur following the polymerization of
-syn into fibrils as an attempt by cells to direct thesea decreased susceptibility for PD (Satoh and Kuroda,
2001) provides some evidence for a role of this enzyme aberrant aggregates for proteasomal degradation. The
E3 ligase responsible for this activity is unknown, butin PD.
These uncertainties notwithstanding, the link between the data from Yang et al. (2003) suggest that parkin
could have such a function. Aggregated -syn can di-UCH-L1 and parkinsonism has led Liu et al. (2002) to
determine that UCH-L1 can also have a previously un- rectly inhibit the proteasome (Figure 3D) (Snyder et al.,
2003), but ubiquitinated -syn inclusions may also actrecognized ubiquityl ligase-like activity that acts to in-
crease polyubiquitination of mono- or diubiquitinated as sinks for functional proteasomes. Polyubiquitinated
-syn within inclusions may recruit 26S proteasomes,-syn, at least in vitro (see Figure 3C). Interestingly, the
Ser18Tyr polymorphism in UCHL-1 displays a dramatic which may be unable to unfold and degrade these stable
aggregates (see Figure 3E). This hypothesis is consis-reduction of ubiquityl ligase activity in vitro, with no
changes in the hydrolase activity (Liu et al., 2002). The tent with a reduction in functional proteasome activity
in the SN of PD patients (McNaught and Jenner, 2001)Ile93Met substitution also results in reduced (50%) li-
Review
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Hochstrasser, M. (1996). Ubiquitin-dependent protein degradation.and the presence of proteasomal subunits in LBs (It et
Annu. Rev. Genet. 30, 405–439. 1996.al., 1997). Since cultured dopaminergic neurons seem
Hughes, A.J., Daniel, S.E., and Lees, A.J. (2001). Improved accuracyparticularly susceptible to proteasomal inhibition, a
of clinical diagnosis of Lewy body Parkinson’s disease. Neurologymoderate reduction in functional proteasomes may con-
57, 1497–1499.tribute to their selective vulnerability.
Imai, Y., Soda, M., and Takahashi, R. (2000). Parkin suppressesIn conclusion, a panoply of evidence suggests that the
unfolded protein stress-induced cell death through its E3 ubiquitin-impairment of ubiquitination pathways and proteasomal
protein ligase activity. J. Biol. Chem. 275, 35661–35664.
function may be a unifying mechanism responsible for
Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., and Takahashi,the degeneration of dopaminergic neurons. However,
R. (2001). An unfolded putative transmembrane polypeptide, which
the evidence suggesting that the various gene products can lead to endoplasmic reticulum stress, is a substrate of Parkin.
(i.e -syn, parkin, and UCH-L1) linked to familial forms Cell 105, 891–902.
of parkinsonism may directly interact is still tentative, Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Naka-
and some of these findings may be biased by experi- yama, K.I., and Takahashi, R. (2002). CHIP is associated with Parkin,
a gene responsible for familial Parkinson’s disease, and enhancesmental designs to find such interactions. It is possible
its ubiquitin ligase activity. Mol. Cell 10, 55–67.that alterations in the properties of -syn, parkin, and
UCH-L1 can independently impair proteasomal function Ii, K., Ito, H., Tanaka, K., and Hirano, A. (1997). Immunocytochemical
co-localization of the proteasome in ubiquitinated structures in neu-by distinct mechanisms, and parkin might not be in-
rodegenerative diseases and the elderly. J. Neuropathol. Exp. Neu-volved in the etiology of classical PD. Although several
rol. 56, 125–131.putative parkin substrates have been identified, it is pos-
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y.,sible that the accumulation of a single parkin substrate
Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998).is sufficient to cause dopaminergic neuron death. Never-
Mutations in the parkin gene cause autosomal recessive juvenile
theless, diverse mechanisms impairing proteasomal- parkinsonism. Nature 392, 605–608.
mediated protein degradation, affecting either overall
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E.,
function or specific substrates, may independently or Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T., et al.
cooperatively culminate in the selective demise of dopa- (1998). The ubiquitin pathway in Parkinson’s disease. Nature 395,
451–452.minergic neurons.
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